Next Generation mRNA Immunotherapies for Cancer and Autoimmune Diseases
Integrating the fields of RNA, immunology and medicine, our proprietary platform provides clinical solutions by matching therapeutic modalities to disease conditions, including by using autologous cell therapies, in vivo cell programming using mRNA, RNA-based gene-editing using RetroT™ and multi-targeted biologics
Developed by leading scientists and clinicians who specialize in oncology, immunology, cell therapy, synthetic biology, and translational medicine, Myeloid’s proprietary ATAK™ platform, mRNA & tri-specific biologic technologies redirect & reprogram cells of the innate immune system to kill cancer.
Our therapies incorporate advanced methods in cell & gene therapy, combining immunology, genetics, cell biology & protein science to improve the lives of patients in need.
